Connect with us

Technology

British Technology company, C the Signs, selected by the White House-Backed Accelerator Programme, CancerX, to half Cancer Deaths

Published

on

LONDON, Feb. 27, 2024 /PRNewswire/ — C the Signs, a British AI technology company founded by NHS Doctors at the forefront of early cancer detection, has been announced as part of the inaugural cohort of the White House CancerX Accelerator programme.

CancerX was unveiled by the White House in a landmark announcement last year to spearhead innovation in oncology. The initiative aims to achieve the ambitious ‘Cancer Moonshot’ goals set by the administration: to reduce cancer mortality by at least 50% over the next 25 years, and to enhance the quality of life for individuals and families living with and surviving cancer. The CancerX Accelerator programme aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations.

C the Signs is an AI cancer prediction platform that identifies patients at risk of cancer at the earliest and most curable stage of the disease. It has so far detected over 25,000 patients with cancer through its innovative AI approach, with a 98% accuracy in ruling in or out cancer risk.  It was selected as one of 16 companies – and the only British company – to be part of the first CancerX Accelerator, C the Signs was selected as it represents one of the most progressive and effective ways of driving digital innovation in oncology.

Dr. Bea Bakshi, CEO & Co-Founder of C the Signs, says:

“As a doctor, I am deeply moved and profoundly grateful for our selection to participate in the inaugural CancerX accelerator. Launched by the White House, this initiative marks a significant step toward realizing the Cancer Moonshot’s vision of a 50% reduction in cancer mortality. At C the Signs, our mission is firmly rooted in the belief that early detection can change the course of this disease, aiming for a future where surviving cancer is the norm rather than the exception. The success we’ve achieved within the UK’s National Health Service so far fills me with immense pride and hope. As we embark on this journey in the United States, I am incredibly enthusiastic about collaborating with the brightest minds in oncology and industry pioneers; what we can collectively achieve is boundless. This is more than just an opportunity; it’s a pivotal moment to lead with heart and affect meaningful change.”

Aphrodite Spanou, Director of Healthcare UK, Department of Health and Social Care, NHS England and the Department for Business and Trade, says:

“We are delighted for C the Signs for being selected as one of the inaugural companies, by the White House’s CancerX Accelerator. This recognition is a testament to the UK’s leadership in healthcare innovation and our capacity to create technology solutions with a global impact. C the Signs’ work in early cancer detection not only exemplifies British ingenuity but also aligns perfectly with our objectives of showcasing how local innovations can have international reach and significance.”

C the Signs was selected from hundreds of applicants after an intensive evaluation process involving three rounds of judging and will now have the unprecedented opportunity to collaborate with the CancerX Champions from leading cancer and technology innovators including AstraZeneca, Intel, Dell Technologies, AWS, Debiopharm Innovation Fund, Mass Challenge, Reveal HealthTech, Atrium Health, Oncology Ventures, and UC Davis Health.

NOTES FOR EDITORS:

ABOUT CANCERX:
Part of the U.S. Cancer Moonshot initiative, CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer. Co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center, alongside the Office of the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), it convenes the many diverse stakeholders needed to unleash the power of innovation to create a future that’s free of cancer burden. To learn more or participate in CancerX’s pre-competitive, evidence-generating efforts; Accelerator cohort; or demonstration projects, visit www.cancerx.health

ABOUT THE CANCERX ACCELERATOR:
The CancerX Accelerator program aims to promote and fortify digital innovations in oncology by providing promising startups an opportunity to collaborate with leading cancer organizations. Startup participants benefit from valuable mentorship, comprehensive training and direct access to key players in the health care industry, including providers, payers and pharmaceutical companies. This collaborative environment enables startups to develop, test and implement their cancer focused innovation on a larger scale.
https://cancerx.health/accelerator/

ABOUT THE 16 START-UPS:
A team of Accelerator Champions and judges from the CancerX community led three rounds of judging earlier this year to select this impressive cohort group. The full list of startups includes: The Blue Box, C the Signs, Cancer Insights, Curvia, EnteroTrack, Gesund.ai, Gray Oncology, LindAI, Mika Health, Navya, Oatmeal Health, Orbit Genomics, Realyze Intelligence, Reimagine Care, SurvivorPlan, and Xanthos.

ABOUT THE PROGRAMME:

As a member of the CancerX accelerator, start-ups will now participate in a rich, 4-month program where they will:

Engage with members of the healthcare ecosystem to test and validate their solutions.Get expert guidance from CancerX Mentors.Graduate with a roadmap to successfully scale our company, an opportunity to move forward with our sponsor, and a community that will continue to support our development.

FURTHER INFORMATION:

–  For further information on The White House Cancer Moonshot Announcement
https://www.whitehouse.gov/briefing-room/statements-releases/2022/02/02/fact-sheet-president-biden-reignites-cancer-moonshot-to-end-cancer-as-we-know-it/#:~:text=Based%20on%20the%20progress%20made%20and%20the%20possibility,and%20their%20families%20living%20with%20and%20surviving%20cancer.
–  For further questions or queries on CancerX: laura@dimesociety.org
–  For the CancerX logo (Horizontal + Vertical)
–  For further information on C the Signs: www.cthesigns.com
–  For further information for press or media queries please contact: Charlotte Beams, Communications Officer, charlottebeames@cthesigns.net

ABOUT HEALTHCARE UK:

Healthcare UK is a joint initiative of the Department of Health and Social Care, NHS England and the Department for Business and Trade. Healthcare UK promotes the British healthcare sector internationally to drive export opportunities and works with the NHS to strengthen its capacity to operate and succeed internationally.

View original content:https://www.prnewswire.com/news-releases/british-technology-company-c-the-signs-selected-by-the-white-house-backed-accelerator-programme-cancerx-to-half-cancer-deaths-302071760.html

SOURCE C the Signs

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Real-World Study of Over 185,000 Users Finds Engagement with UpLife Digital Mental Health App Yields Significant Reductions in Depression and Anxiety

Published

on

By

Five-year evaluation shows a clear “dose–response” link between deeper engagement with UpLife’s CBT-based ‘Journeys’ programs and greater depression and anxiety symptom improvement

LEESBURG, Va., July 21, 2026 /PRNewswire-PRWeb/ — UpLife Inc, a digital mental health and self-therapy platform, today announced a set of research findings from a large real-world evaluation of its app, showing that people who engaged with the platform reported statistically significant reductions in symptoms of depression and anxiety over time. The evaluation drew on five years of real-world data from an engaged user base of more than 185,000 people across the United States and 197 other countries worldwide.

“These results reflect what we hear from users every day, now backed by data at real-world scale. What stands out is the dose–response signal where the people who lean into the work by completing their Journeys and doing the exercises are the ones who get the most out of it.” Jeff Musa, CEO, UpLife

The research analysis examined anonymized data collected between 2021 and 2026 using three validated clinical outcome measures: the PHQ-9 (depression), the GAD-7 (anxiety), and the WHO-5 (well-being). Among UpLife users who completed assessments at baseline and follow-up, depression and anxiety scores decreased significantly over time.

In the fully adjusted analysis, average depression scores (PHQ-9) fell by approximately 3.7 points; moving the typical UpLife user from the “moderately severe” range toward the “moderate” range. Anxiety scores (GAD-7) showed comparable significant reductions over time.

A clear dose–response relationship

One of the study’s central findings was a consistent dose–response pattern regarding the relationship between engagement and outcomes. Users who completed UpLife’s CBT-based ‘Journeys’ experienced a reduction in their symptoms. The study also found that the completion of additional Journeys were associated with a further measurable decrease in their assessment scores, even after accounting for subscription type and other factors. Notably, depth of engagement with therapeutic content was a stronger predictor of improvement than simply the amount of time spent in the app.

“These results reflect what we hear from users every day, now backed by data at real-world scale. What stands out most is the dose–response signal where the people who lean into the work by completing their Journeys and doing the exercises are the ones who get the most out of it. That tells us our job is to keep building an experience that helps people stay engaged, because engagement is where the clinical value lives.” — Jeff Musa, Chief Executive Officer, UpLife

Built on cognitive behavioral therapy

UpLife delivers evidence-based psychological education and interventions grounded in the principles of cognitive behavioral therapy (CBT) through five core features: structured Journeys, a Daily Plan, a Mood Tracker, journaling, and an AI assistant (“Lila”) that recommends relevant content from the platform. The app does not provide AI-generated therapy; its assistant only directs users to content that has been created, curated, and reviewed by clinicians.

For clinicians, UpLife also offers a HIPAA-compliant therapist portal that supports a Blended Care model, allowing providers to extend therapeutic support between sessions through structured digital programs, progress tracking, and shared assessments.

The platform has also been extensively used in humanitarian settings. Through UpLife’s Ukraine Humanitarian Gift Program, tens of thousands of users in Ukraine have received full, free access to a localized version of the app through UpLife’s Ukraine Humanitarian Gift Program.

About the evaluation

The study used an observational pre–post design based on real-world data and was conducted in accordance with the ethical principles of the Declaration of Helsinki. As an observational evaluation without a control group, it demonstrates associations between app engagement and symptom improvement rather than establishing causation, and well-being scores (WHO-5) did not change significantly over the study period. The findings add to a growing body of research suggesting that CBT-based digital interventions can be associated with meaningful symptom reduction, while underscoring the central role of sustained user engagement.

About UpLife

Founded in 2019, UpLife is a digital mental health and self-guided therapy platform that is designed to help people improve their emotional well-being, build healthier thinking patterns, and develop positive daily habits through structured, evidence-based psychological programs. UpLife also provides a secure, HIPAA-compliant portal to help therapists and health systems to extend care beyond the through a Blended Care Therapy model. Learn more at www.uplifecare.com.

Media Contact

Matt Landry, UpLife, 1 617-699-7205, matt@thesecondrow.net, https://www.uplifecare.com/ 

View original content:https://www.prweb.com/releases/real-world-study-of-over-185-000-users-finds-engagement-with-uplife-digital-mental-health-app-yields-significant-reductions-in-depression-and-anxiety-302829280.html

SOURCE UpLife

Continue Reading

Technology

TruHeight Joins Nordstrom and JCPenney Marketplaces as Wellness Brands Reshape the Department Store

Published

on

By

Family nutrition brand’s newest retail partnerships reflect a broader shift: health and wellness products are becoming a staple of platforms once reserved for fashion and apparel

LAS VEGAS, July 21, 2026 /PRNewswire/ — TruHeight, the family nutrition brand, today announced it is joining the Nordstrom Marketplace and the JCPenney Marketplace, bringing its lineup of clean-label vitamins, gummies, protein shakes, and everyday nutrition products to two of America’s most iconic department store names.

The partnerships place TruHeight at the center of one of retail’s most notable shifts. Department stores and fashion-first marketplaces, long defined by clothing, shoes, and accessories, are rapidly expanding into health and wellness as consumers increasingly treat wellness as part of their everyday lifestyle rather than a separate shopping trip. For a generation of shoppers, the same platforms where they buy back-to-school outfits and activewear are becoming destinations for the products that fuel those activities.

“Five years ago, you wouldn’t expect to find a family nutrition brand next to denim and sneakers,” said Justin Rapoport, Co-CEO of TruHeight. “Today, wellness is part of how families shop for everything. Nordstrom and JCPenney recognize that, and we’re proud to bring family nutrition to their marketplaces.”

The move extends a period of rapid retail growth for TruHeight, which launched in 5,000 CVS stores nationwide in June following its national debut at Target earlier this year, and is also available at iHerb and on Amazon. With the addition of Nordstrom and JCPenney, TruHeight’s products will reach shoppers across drug, mass, e-commerce, and department store channels.

“Every retailer we add is a signal of the trust families place in our brand,” said Eden Stelmach, Co-Founder of TruHeight. “Department stores are where families have shopped together for generations. Meeting them there with simple, clean nutrition products is a natural next step.”

TruHeight products will be available on the Nordstrom and JCPenney marketplaces in the coming weeks, joining the brand’s existing availability at CVS, Target, iHerb, Amazon, and truheightvitamins.com.

About TruHeight
TruHeight is a family nutrition brand offering clean-label vitamins, gummies, protein shakes, and everyday nutrition products for kids, teens, and active families. Founded with a commitment to simple ingredients and convenient formats, TruHeight products are available at major retailers nationwide and online at truheightvitamins.com.

Media Contact
TruHeight Vitamins
Kim Brown
419189@email4pr.com
4704265920
truheightvitamins.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/truheight-joins-nordstrom-and-jcpenney-marketplaces-as-wellness-brands-reshape-the-department-store-302830436.html

SOURCE TruHeight Vitamins

Continue Reading

Technology

TrendyMinds Founder Trevor Yager Returns as CEO to Lead Agency’s Next Phase of Growth

Published

on

By

Veteran agency leader returns to accelerate TrendyMinds’ AI capabilities and advance the firm’s evolution as a strategic partner helping organizations drive growth, strengthen reputation, and navigate transformation.

INDIANAPOLIS, July 21, 2026 /PRNewswire/ — Trevor Yager has returned as Chief Executive Officer (CEO) of TrendyMinds, the Indianapolis-based agency he founded in 1995, while continuing to serve as Chairman. In this dual role, Yager has resumed direct involvement in day-to-day leadership, working alongside account and delivery teams on client work in addition to setting the agency’s strategic direction. As CEO, he is leading the company’s next phase of growth by advancing the firm’s artificial intelligence (AI) capabilities while strengthening its position as a strategic partner to organizations navigating growth and change.

Yager previously transitioned from CEO to Chairman as part of a planned leadership evolution that reflected both the agency’s maturity and his own exploration of future ownership opportunities. As AI has accelerated the pace of change across the industry, reshaping how organizations operate and compete, he made the decision to step back into the CEO role and lead TrendyMinds through its next chapter directly.

“Moving into the Chairman role was the right decision at the time because the Board, including myself, believed TrendyMinds needed to demonstrate it could thrive beyond its founder,” said Yager. “But after more than 30 years of leading through every major technology shift, I believe artificial intelligence represents one of the greatest opportunities our industry has ever seen. The environment shifted fast enough that it made sense for me to step back in and lead it personally, continuing to build the capabilities our clients will need and position the agency for what’s next.”

Beginning in 2019, TrendyMinds became increasingly intentional about optimizing the artificial intelligence, machine learning, and automation capabilities already embedded within the technologies used across the agency. Following a comprehensive assessment of AI-enabled tools and workflows, the agency integrated AI across strategy, research, creative development, marketing operations, and internal business processes while establishing governance, security, and data protection standards to support responsible implementation.

By transforming its own business first, TrendyMinds refined its methodologies, validated new approaches, and built the operational discipline that now informs how it evaluates AI opportunities with clients. Today, TrendyMinds continues to expand its internal AI capabilities through a dedicated team of AI transformation specialists, developing proprietary workflows, audience intelligence tools, and implementation frameworks. Drawing on that experience, the agency helps clients responsibly evaluate and implement AI in ways that align with their business objectives, regulatory requirements, and governance standards.

That experience also enables TrendyMinds to support clients developing innovative AI technologies, including a leading healthcare AI innovator. By combining firsthand AI transformation experience with strategic consulting, communications, and market positioning expertise, the agency helps organizations communicate complex technologies, build trust with stakeholders, and accelerate market adoption.

Founded as a traditional marketing agency more than 30 years ago, TrendyMinds has continually evolved alongside the changing needs of its clients, bringing together strategic consulting, integrated marketing, communications, creative, thought leadership, media relations, digital strategy and development, research, analytics, and emerging technologies.

About TrendyMinds

TrendyMinds is the Agency of Preference®, a multidisciplinary consulting partner helping organizations accelerate growth, strengthen and protect reputation, and navigate transformation. Founded in Indianapolis in 1995, the firm has spent more than 30 years uniting strategic consulting, communications, marketing, creative, technology, and data-driven insight into a single integrated practice built to solve complex business challenges.

Learn more at TrendyMinds.com.

Media Contact:
Claire Gregory
419095@email4pr.com | 317.902.6973

View original content to download multimedia:https://www.prnewswire.com/news-releases/trendyminds-founder-trevor-yager-returns-as-ceo-to-lead-agencys-next-phase-of-growth-302830444.html

SOURCE TrendyMinds

Continue Reading

Trending